286 related articles for article (PubMed ID: 33571554)
1. Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model.
Wang Y; Gu L; Yang HM; Zhang H
Neurotoxicology; 2021 May; 84():14-29. PubMed ID: 33571554
[TBL] [Abstract][Full Text] [Related]
2. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
Ferrigno A; Vairetti M; Ambrosi G; Rizzo V; Richelmi P; Blandini F; Fuzzati-Armentero MT
Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):695-703. PubMed ID: 25904005
[TBL] [Abstract][Full Text] [Related]
3. PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson's Disease.
Luo WY; Xing SQ; Zhu P; Zhang CG; Yang HM; Van Halm-Lutterodt N; Gu L; Zhang H
Neurotherapeutics; 2019 Jul; 16(3):761-783. PubMed ID: 31073978
[TBL] [Abstract][Full Text] [Related]
4. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of metabotropic glutamate receptor 5 inhibits hepatoma development in a neurotoxin rotenone-induced Parkinson's disease model.
Bai XX; Gu L; Yang HM; Xi SS; Xia N; Zhang S; Zhang H
Toxicol Lett; 2018 May; 288():71-81. PubMed ID: 29458170
[TBL] [Abstract][Full Text] [Related]
6. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
7. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
8. Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson's disease.
Huang YY; Zhang Q; Zhang JN; Zhang YN; Gu L; Yang HM; Xia N; Wang XM; Zhang H
Brain Behav Immun; 2018 Jul; 71():93-107. PubMed ID: 29649522
[TBL] [Abstract][Full Text] [Related]
9. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
[TBL] [Abstract][Full Text] [Related]
10. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
11. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
Black YD; Xiao D; Pellegrino D; Kachroo A; Brownell AL; Schwarzschild MA
Neurosci Lett; 2010 Dec; 486(3):161-5. PubMed ID: 20854878
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
14. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
15. FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models.
Ren M; Han M; Wei X; Guo Y; Shi H; Zhang X; Perez RG; Lou H
Neurochem Res; 2017 Feb; 42(2):686-696. PubMed ID: 27943027
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
17. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
Chen L; Cheng L; Wei X; Yuan Z; Wu Y; Wang S; Ren Z; Liu X; Liu H
Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221
[TBL] [Abstract][Full Text] [Related]
18. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
[TBL] [Abstract][Full Text] [Related]
19. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Morin N; Morissette M; Grégoire L; Di Paolo T
Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
